Eurofins-Cerep (XPAR:ALECR) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALECR Eurofins-Cerep SA XPAR:ALECR
27 GF Score
Price €16,300.00
GF Value €20,317.48
! 4 Warning Signs
View Full Analysis

What is Eurofins-Cerep Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:ALECR vs TMO, DHR, IDXX: Short Interest Comparison

For the Diagnostics & Research subindustry, Eurofins-Cerep's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eurofins-Cerep Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's Short Interest distribution charts can be found below:

* The bar in red indicates where Eurofins-Cerep's Short Interest falls into.


XPAR:ALECR
27GF Score
Eurofins-Cerep SA XPAR:ALECR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?

Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued. The current stock price of €16,300.00 is trading 19.8% below its estimated GF Value™ of €20,317.48.

Key valuation signals for XPAR:ALECR:

  • Short Interest:
  • GF Value™: €20,317.48 vs. price of €16,300.00 (19.8% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eurofins-Cerep Business Description

Address Le bois l Eveque, Celle l Evescault, FRA, 86600
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
27GF Score

Get the complete analysis for XPAR:ALECR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16,300.00
Price
€20,317.48
GF Value